TITLE

Omrix resumes fibrin pad study

PUB. DATE
November 2008
SOURCE
Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the resumption of the Fibrin Pad U.S. Phase II clinical trial in mild-to-moderate bleeding by Omrix Biopharmaceuticals in November 2008. The features of the Fibrin Pad are described. On October 9, the company has announced the suspension of the U.S. Phase II clinical trial following an incident of post-operative bleeding.
ACCESSION #
35066385

 

Related Articles

  • Postoperative Bleeding Halts Fibrin Pad Trial.  // Bioworld Week;10/13/2008, Vol. 16 Issue 41, p4 

    The article cites a report from Omrix Biopharmaceuticals Inc. which reveals that Phase II study of its Fibrin Pad product has been suspended to investigate an incident of postoperative bleeding. The study showed that the Fibrin Pad was superior to Surgicel in controlling mild to moderate soft...

  • Postoperative Bleeding Halts Fibrin Pad Trial; Omrix Falls. Boggs, Jennifer // BioWorld Today;10/10/2008, Vol. 19 Issue 198, p1 

    The article discusses the suspension by Omrix Biopharmaceuticals Inc. of the Phase II study of the Fibrin Pad product to investigate an incident of postoperative bleeding. The Fibrin Pad is made of a biodegradable matrix coated with human fibrinogen and thrombin and is designed to help form...

  • FDA approves Evithrom for bleeding control during surgery.  // Medical Device Daily;8/29/2007, Vol. 11 Issue 165, p9 

    The article reports on the U.S. Food and drug Administration's (FDA) approval of Evithrom, which is a blood-clotting protein used to control bleeding during surgery manufactured by Omrix Biopharmaceuticals. Evithrom is derived from human plasma that is obtained from carefully screened and tested...

  • Biotechnology.  // PharmaWatch: Monthly Review;Jan2009, Vol. 8 Issue 1, p33 

    The article offers information related to biotechnology. Omrix Biopharmaceuticals Inc. has been acquired by Johnson & Johnson for approximately $438 million in a cash tender offer. Belgian biotechnology company UCB has reported positive results from two Phase III trials of Cimzia. Jazz...

  • New FDA Approvals.  // Drug Formulary Review;Mar2008 Supplement, Vol. 24, Special section p3 

    The article reports on several recent approvals by the Food and Drug Administration in the U.S. Accordingly, the agency approves Biogen Idec Inc.'s Tysabri (natalizumab) for treating moderate-to-severe Crohn's diseases in patients with evidence of inflammation. Moreover, the agency also expanded...

  • FDA licenses human thrombin product. Traynor, Kate // American Journal of Health-System Pharmacy;10/1/2007, Vol. 64 Issue 19, p1994 

    The article reports on the approval of the Food and Drug Administration (FDA) of the licensing of Evithrom human thrombin as an aid to homeostasis during surgery. FDA said that Evithrom is the first human thrombin product to be approved in more than 50 years and the only product currently...

  • Topical thrombin of human origin OK'd.  // Drug Topics;9/17/2007, Vol. 151 Issue 18, p8 

    The article reports on the U.S. Food and Drug Administration's approval of Evithrom from Omrix Biopharmaceuticals, the first thrombin derived from human plasma in 53 years and the only product currently licensed in the country. The topical thrombin is indicated to stop minor bleeding from...

  • Topical human thrombin helps arrest bleeding. Belden, Heidi // Drug Topics;10/22/2007, Vol. 151 Issue 20, Special Section p4 

    The article offers information on the topical human thrombin which helps prevent bleeding. It is posed that Evithrom is from Omrix Biopharmaceuticals and Johnson & Johnson Wound Management. Relative to this, the Biological License Application was cleared by the United States Food and Drug...

  • Prospective Trial of Endoscopic Clips Versus Combination Therapy in Upper GI Bleeding (PROTECCT—UGI Bleeding). Saltzman, John R.; Strate, Lisa L.; Di Sena, Veruska; Huang, Christopher; Merrifield, Benjamin; Ookubo, Rie; Carr-Locke, David L. // American Journal of Gastroenterology;Jul2005, Vol. 100 Issue 7, p1503 

    BACKGROUND : It is not known if combination therapy of epinephrine injection and multipolar electrocoagulation or hemoclips are a more efficient or effective treatment for patients with acute nonvariceal upper gastrointestinal (GI) bleeding. METHODS : Adult patients with active nonvariceal upper...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics